4Akuta N , Kumada H. Influence of hepatitis B virus genotypes on the response to antiviral therapies[J].J Antimicrob Chemother. 2005 ; 55 : 13921421
5Thursz M. Genetic susceptibility in chronic viral hepatitis[J] . Antiviral Res. 2001 ;52:11321161
6Nakoo K, Nakata K, Yamashita M , et al. P48 ( ISGF- 3gamma) is involved in interferon-alpha induced suppression of hepatitis B virus enhancer- 1 activity[J] .J Biol Chem, 1999 , 274(40) : 28075.
7Radecke K, Protzer U, Trippler M, et al. Selection of hepatitis B virus variants with aminoacid substitutions inside the the core antigen during interferon-alpha therapy[J] . J Med Virol 2000; 62:479 - 486
8Zampino R, Marrone A, Cirillo G, del Giudice EM, et al. Sequential analysis of hepatitis B virus rare promoter and precore in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment[J] .J Viral Hepat. 2002; 9: 183- 188.
9Cabrerizo M, Bartolome J, Otero M, et al. Sequence variation of hepatitis B virus precore-core open reading frame isolated from serum and liver of children with chronic hepatits B before and after interferon treatment[J} .J Med Virol 1999; 58:208- 214.
10Karasawa T, Aizawa Y, et al. Gentic hetercgeneity in the precore refion of hepatitis B virus in hepatitis B antigennefative chronic hepatitis B patients: spontaneous seroconversion and interferon- induced seroconversion[J].J Med Virol 1995,45:373 - 380.
